Pediatrix Medical Group, Inc. - 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Pediatrix Medical Group, Inc., covering the period ended September 30, 1999. The Company operates as a medical group providing neonatal and pediatric services. As of November 7, 1999, there were 15,575,185 shares of common stock outstanding.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 1999 | Nine Months Ended Sept 30, 1999 |
|---|---|---|
| Net Patient Service Revenue | $57.9 million | $168.5 million |
| Net Income | $5.0 million | $20.0 million |
| Diluted EPS | $0.32 | $1.27 |
| Operating Cash Flow (9 months) | $14.2 million | |
| Cash and Equivalents (Sept 30, 1999) | $0.4 million | |
| Working Capital | Deficit of $24.8 million | |
| Debt (Line of Credit) | $56.8 million outstanding (of $75M facility) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 17.4% (Q3) and 26.4% (9 months) year-over-year, driven primarily by acquisitions of ten physician groups. However, same-unit revenue declined 7.1% (Q3) and 3.7% (9 months) due to lower patient acuity.
- Profitability: Net income decreased 34.7% in Q3 and 3.9% for the nine months compared to 1998. Operating income dropped 26.2% in Q3 but remained flat for the nine-month period.
- Expense Increases: Salaries and benefits rose 29.7% (Q3) and 32.2% (9 months) due to new physician hires and support staff. Supplies and operating expenses surged 61.5% (Q3) and 59.1% (9 months), attributed to legal fees from government investigations and new outpatient offices.
- Liquidity Shift: The Company moved from a working capital surplus of $14.9 million at year-end 1998 to a deficit of $24.8 million. This is largely due to the reclassification of the line of credit as a current liability.
Outlook, Risks, and Contingencies
- Legal Proceedings: The Company is facing a consolidated federal securities class action lawsuit alleging false statements regarding accounting practices and revenue recognition. Plaintiffs seek undetermined damages. The Company intends to defend vigorously.
- Government Investigations: State investigators in Arizona, Colorado, and Florida have issued requests and subpoenas regarding billing practices. The Company is cooperating but cannot predict the material impact.
- Financing: With $18.2 million remaining on its $75 million line of credit, management is evaluating options for long-term financing.
- Year 2000 Compliance: The Company has completed testing of critical systems. Estimated total costs are under $500,000. Contingency plans are in place for potential third-party failures.
Investor Verification Checklist
- Verify the status and potential financial exposure of the consolidated federal securities class action lawsuit.
- Monitor the outcome of state billing practice investigations in Arizona, Colorado, and Florida.
- Assess the Company's ability to secure long-term financing given the current working capital deficit and high utilization of the credit line.
- Review the sustainability of same-unit revenue declines amidst continued acquisition-driven growth.
- Confirm the impact of expensing acquisition-related costs (previously capitalized) on future earnings.